Terms: = Endocrine gland cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Treatment
466 results:
1. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial.
Jimenez C; Habra MA; Campbell MT; Tamsen G; Cruz-Goldberg D; Long J; Bassett R; Dantzer R; Balderrama-Brondani V; Varghese J; Lu Y
Lancet Oncol; 2024 May; 25(5):658-667. PubMed ID: 38608693
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical features of patients with metastatic pheochromocytoma/paraganglioma].
Cui YY; Zhou Y; Gao YJ; Li TY; Wang Y; Zhang WQ; Zhou T; Chen S; Tong AL
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1174-1179. PubMed ID: 38583049
[No Abstract] [Full Text] [Related]
3. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma.
Cao Z; Jing Y; Cheng C; Wang F; Guan M; Zhang K; Jiao J; Ruan L; Chen Z
Front Biosci (Landmark Ed); 2024 Mar; 29(3):119. PubMed ID: 38538250
[TBL] [Abstract] [Full Text] [Related]
4. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
[TBL] [Abstract] [Full Text] [Related]
5. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.
Padilla-Iserte P; Iváñez M; Muruzabal JC; Navarro R; Díaz-Feijoo B; Iacoponi S; García-Pineda V; Díaz C; Utrilla-Layna J; Gil-Moreno A; Serra A; Gilabert-Estellés J; Martínez Canto C; Tejerizo Á; Lago V; Cárdenas-Rebollo JM; Domingo S;
Eur J Surg Oncol; 2024 Apr; 50(4):108263. PubMed ID: 38492526
[TBL] [Abstract] [Full Text] [Related]
6. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the treatment of Ovarian cancer.
Wang JY; Gross M; Urban RR; Jorge S
Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
[TBL] [Abstract] [Full Text] [Related]
7. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression.
Cao Z; Guan M; Cheng C; Wang F; Jing Y; Zhang K; Jiao J; Ruan L; Chen Z
Pathol Res Pract; 2024 Feb; 254():155046. PubMed ID: 38266456
[TBL] [Abstract] [Full Text] [Related]
8. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms.
Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
[TBL] [Abstract] [Full Text] [Related]
9. Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian cancer Murine Xenografts.
Demuytere J; Carlier C; Van de Sande L; Hoorens A; De Clercq K; Giordano S; Morosi L; Matteo C; Zucchetti M; Davoli E; Van Dorpe J; Vervaet C; Ceelen W
Int J Nanomedicine; 2024; 19():429-440. PubMed ID: 38260242
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
[TBL] [Abstract] [Full Text] [Related]
11. Connexin 36 Mediated Intercellular Endoplasmic Reticulum Stress Transmission Induces SSTA Resistance in Growth Hormone Pituitary Adenoma.
Wang Z; Lei Z; Wang Q; Jiang Q; Zhang Z; Liu X; Xing B; Li S; Guo X; Liu Y; Li X; Qi Y; Shu K; Zhang H; Huang Y; Lei T
Int J Biol Sci; 2024; 20(2):801-817. PubMed ID: 38169563
[TBL] [Abstract] [Full Text] [Related]
12. Management of phaeochromocytoma and paraganglioma in patients with germline sdhb pathogenic variants: an international expert Consensus statement.
Taïeb D; Nölting S; Perrier ND; Fassnacht M; Carrasquillo JA; Grossman AB; Clifton-Bligh R; Wanna GB; Schwam ZG; Amar L; Bourdeau I; Casey RT; Crona J; Deal CL; Del Rivero J; Duh QY; Eisenhofer G; Fojo T; Ghayee HK; Gimenez-Roqueplo AP; Gill AJ; Hicks R; Imperiale A; Jha A; Kerstens MN; de Krijger RR; Lacroix A; Lazurova I; Lin FI; Lussey-Lepoutre C; Maher ER; Mete O; Naruse M; Nilubol N; Robledo M; Sebag F; Shah NS; Tanabe A; Thompson GB; Timmers HJLM; Widimsky J; Young WJ; Meuter L; Lenders JWM; Pacak K
Nat Rev Endocrinol; 2024 Mar; 20(3):168-184. PubMed ID: 38097671
[TBL] [Abstract] [Full Text] [Related]
13. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Fischer A; Kloos S; Remde H; Dischinger U; Pamporaki C; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Bechmann N; Hantel C; Mohr H; Pellegata NS; Bornstein SR; Kroiss M; Auernhammer CJ; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
Eur J Endocrinol; 2023 Nov; 189(5):546-565. PubMed ID: 37949483
[TBL] [Abstract] [Full Text] [Related]
14. Curcumin induces mitophagy by promoting mitochondrial succinate dehydrogenase activity and sensitizes human papillary thyroid carcinoma BCPAP cells to radioiodine treatment.
Zhang L; Qiu L; Xu S; Cheng X; Wu J; Wang Y; Gao W; Bao J; Yu H
Toxicol In Vitro; 2023 Dec; 93():105669. PubMed ID: 37634662
[TBL] [Abstract] [Full Text] [Related]
15. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M; Fassnacht M; Perotti P; Libé R; Kastelan D; Lacroix A; Arlt W; Haak HR; Loli P; Decoudier B; Lasolle H; Quinkler M; Haissaguerre M; Chabre O; Caron P; Stigliano A; Giordano R; Zatelli MC; Bancos I; Fragoso MCBV; Canu L; Luconi M; Puglisi S; Basile V; Reimondo G; Kroiss M; Megerle F; Hahner S; Kimpel O; Dusek T; Nölting S; Bourdeau I; Chortis V; Ettaieb MH; Cosentini D; Grisanti S; Baudin E; Berchialla P; Bovis F; Sormani MP; Bruzzi P; Beuschlein F; Bertherat J; Berruti A
Lancet Diabetes Endocrinol; 2023 Oct; 11(10):720-730. PubMed ID: 37619579
[TBL] [Abstract] [Full Text] [Related]
16. Gemcitabine Inhibits the Progression of Pancreatic cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner.
Cao P; Zhang W; Qiu J; Tang Z; Xue X; Feng T
Cancer Res Treat; 2024 Jan; 56(1):259-271. PubMed ID: 37591781
[TBL] [Abstract] [Full Text] [Related]
17. Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells.
Xu H; Zeng S; Wang Y; Yang T; Wang M; Li X; He Y; Peng X; Li X; Qiao Q; Zhang J
J Pathol; 2023 Oct; 261(2):210-226. PubMed ID: 37565313
[TBL] [Abstract] [Full Text] [Related]
18. Reduced uptake pattern on
de Jong MC; Pinto D; Parameswaran R
J Surg Oncol; 2023 Oct; 128(5):764-768. PubMed ID: 37403579
[TBL] [Abstract] [Full Text] [Related]
19. Papillary thyroid cancer immune phenotypes via tumor-infiltrating lymphocyte spatial analysis.
Nam M; Yang W; Kim HS; Park J; Park G; Kim S; Song S; Ock CY; Wang VG; Chuang JH; Chae YK
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37279258
[TBL] [Abstract] [Full Text] [Related]
20. Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma.
Vallés-Martí A; Mantini G; Manoukian P; Waasdorp C; Sarasqueta AF; de Goeij-de Haas RR; Henneman AA; Piersma SR; Pham TV; Knol JC; Giovannetti E; Bijlsma MF; Jiménez CR
Cell Rep; 2023 Jun; 42(6):112581. PubMed ID: 37269289
[TBL] [Abstract] [Full Text] [Related]
[Next]
